


# VALIDATION OF QYSCORE®’S FULLY AUTOMATED QUANTITATIVE IMAGE SEGMENTATION TOOLS AGAINST AN EXPERT MANUAL GOLD-STANDARD

Elizabeth Gordon<sup>1</sup>, Luca M. Villa<sup>1</sup>, Mathilde Borrot<sup>1</sup>, Thomas Jubault<sup>1</sup>, Nicolas Guizard<sup>1</sup>, the Alzheimer’s Disease Neuroimaging Initiative, Parkinson’s Progressive Markers Initiative Study, Laboratory of Imaging Technologies in Multiple Sclerosis, the Organization for the Advancement of Structured Information Standards Study.

<sup>1</sup>Qynapse, 2-10 rue d’Oradour-sur-Glane, 75015 Paris, France Email: [egordon@qynapse.com](mailto:egordon@qynapse.com)

## BACKGROUND

- Quantitative imaging provides valuable information for early detection, improved confidence in diagnosis, disease progression and treatment response monitoring.
- Measurement of key subcortical regions have been shown to be particularly sensitive to early changes across the spectrum of neurodegenerative dementias
- Manual segmentation is the current gold-standard, but is prohibitively labour-intensive for large scale use, such as in clinical routine, and suffers from individual variability.
- Thus, there is a substantial unmet need for validation of automatic segmentation techniques that perform as accurately as this labour-intensive manual gold-standard and the certification of such algorithms to support patient assessment in clinical routine



## OBJECTIVES

To validate fully automated U-Net segmentation algorithms against expert manual gold-standard segmentations for inclusion into **QyScore®**, an **FDA-approved** and **CE-marked** neuroimaging medical device.

## METHODS

The validation cohort consisted of 50 individuals (mean age: 50.39y ± 21.01, range: 18y–86y, 48% female), with Alzheimer’s Disease (*n*=4), Parkinson’s Disease (*n*=3), Multiple Sclerosis (*n*=6), and Healthy Controls (*n*=37).

- Data were acquired across multiple scanners, with balanced magnetic field strength (48% 1.5T, 52% 3T)


Three expert neuroradiologists manually segmented the caudate, putamen, globus pallidus, thalamus, cerebellum, brainstem, and lateral ventricles on 3DT1 images using itk-SNAP software.

- Consensus expert segmentation was derived using the STAPLE (Simultaneous Truth and Performance Level Estimation) algorithm<sup>1</sup> for each region and segmentations and volumes compared with the fully automated segmentations utilizing a U-Net convolutional neural network architecture within **QyScore®**

Performance was investigated using the Dice Similarity Coefficient (DSC) and concordance assessed with plotted linear regression.

## RESULTS

- Results demonstrated a high degree of agreement between the consensus manual gold-standard and **QyScore®’s** automated segmentation as evidenced by uniformly **high DSC score** (0.81 – 0.95) (Table 1)
- A strong concordance between the volumes, expressed as a percentage of intracranial volume (%ICV), was obtained across all seven structures (Table 1: Figure 1).
- This agreement remained consistent following stratification by field strength, demonstrating generalizability to most clinical imaging centres.
- The DSC for all seven structural markers was equivalent to or higher than the currently reported state-of-the-art automated segmentation methods for each marker<sup>2</sup>



**Figure 1.** Regression analysis plotting volumes, expressed as a percentage of intracranial volume (%ICV), derived from the gold-standard consensus of three expert neuroradiologist’ manual segmentations (y-axis), against QyScore®’s fully-automated U-Net based segmentation algorithm (x-axis) for each of the seven regional markers

**References:** <sup>[1]</sup>Warfield et al., (2004) IEEE Trans Med Imaging, 23(7):903-21  
<sup>[2]</sup> Internal literature review: results available on request  
[egordon@qynapse.com](mailto:egordon@qynapse.com)

## CONCLUSIONS

**QyScore®** produces fast reliable automated segmentations with comparable accuracy to the consensus of expert neuroradiologists.

These findings support the implementation of **QyScore®** in clinical trials and clinical routine to provide fully automated quantitative image analysis in support of diagnosis and monitoring of disease progression and treatment response.